Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.70, No.1, p. 166–176, 2023 |
||
Title: BDNF, sHLA-G, and sTREM-1 are useful blood biomarkers for identifying grade IV glioma patients | ||
Author: Kristina Kluckova, Jan Kozak, Marian Svajdler, Juraj Steno, Viktor Matejcik, Vladimira Durmanova, Eszter Zsemlye, Maria Bucova | ||
Abstract: Inflammation and immunity belong to the main factors influencing tumor growth. In this study, we attempted to identify a profile of biomarkers associated with gliomas. We found decreased serum levels of sTREM-1 (soluble triggering receptor expressed on myelocytes) and increased levels of IL-10 in all grades of glioma patients in comparison with healthy controls (sTREM-1: grade II: p = 0.0051, grade III: p = 0.02, grade IV: p = 0.01; IL-10: grade II: p = 0.0017, grade III: p = 0.03, grade IV: p = 0.007). However, we did not find any combination of tested markers with good sensitivity and specificity in grades II and III of glioma patients to discriminate them from healthy controls. In grade IV glioma patients, two sets of markers showed promising results in distinguishing patients from healthy people. For the first set consisting of four selected markers, sTREM-1, sHLA-G, BDNF, and IL-13, the ROC curves indicate a good discriminatory capability for glioblastoma patients (AUC = 0.9510). The best discriminatory capability for glioblastoma patients (AUC = 0.9534) was found for the second set consisting of three selected markers sTREM-1, sHLA-G, and BDNF with 79.2% sensitivity and 94.1% specificity. |
||
Keywords: BDNF; HLA-G; TREM-1; IL-13; glioma | ||
Published online: 27-Jan-2023 | ||
Year: 2023, Volume: 70, Issue: 1 | Page From: 166, Page To: 176 | |
doi:10.4149/neo_2023_221129N1147 |
||
|
download file |
|